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Exam [MMSE] 29.3 ± 1.1) were genotyped for APOE4 carrier-status and received 3 Tesla magnetic reso-
nance imaging (MRI) for blood oxygen level-dependent functional magnetic resonance imaging (MRI) at
rest, three-dimensional (3D)-gradient echo (six echoes) for cortical gray-matter, non-heme iron by quanti-
tative susceptibility mapping, and 18F-flutemetamol positron emission tomography for amyloid-฀. Results
A spatial pattern consistent with the default mode network (DMN) could be identified by independent
component analysis. DMN activity was enhanced in APOE4 carriers and related to cortical iron burden.
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Introduction: Apolipoprotein E 𝜀4 (APOE4)–related genetic risk for sporadic
Alzheimer’s disease is associated with an early impairment of cognitive brain net-
works. The current study determines relationships between APOE4 carrier status,
cortical iron, and cortical network-functionality.
Methods: Sixty-nine cognitively healthy old-aged individuals (mean age [SD] 66.1 [±
7.2] years; Mini-Mental State Exam [MMSE] 29.3 ± 1.1) were genotyped for APOE4
carrier-status and received 3 Tesla magnetic resonance imaging (MRI) for blood oxy-
gen level–dependent functional magnetic resonance imaging (MRI) at rest, three-
dimensional (3D)–gradient echo (six echoes) for cortical gray-matter, non-heme iron by
quantitative susceptibilitymapping, and 18F-flutemetamol positron emission tomogra-
phy for amyloid-𝛽
Results: A spatial pattern consistent with the default mode network (DMN) could be
identified by independent component analysis. DMN activity was enhanced in APOE4
carriers and related to cortical iron burden. APOE4 and cortical iron synergistically
interacted with DMN activity. Secondary analysis revealed a positive, APOE4 associ-
ated, relationship between cortical iron andDMN connectivity.
Discussion:Our findings suggest that APOE4 moderates effects of iron on brain func-
tionality prior tomanifestation of cognitive impairment.
K EYWORD S
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Alzheimer’s disease
1 INTRODUCTION
Apolipoprotein E (apoE) is an essentialmediator for fatmetabolismand
facilitates cholesterol handling in the central nervous system (CNS).1
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
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The Apolipoprotein E 𝜀4 allele (APOE4) is the strongest known genetic
risk factor for sporadicAlzheimer’s disease (AD).2–4 In addition, several
studies have demonstrated associations between APOE4 with estab-
lished clinical phenotypes and pathological hallmarks of increased risk
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for AD. These include mild cognitive impairment,5,6 increased bur-
den of brain amyloid-𝛽 (A𝛽),7–11 CNS proteinopathy,12,13 metabolic
disorder,14,15 and vascular disease.16,17
Cognitive dysfunction in AD is preceded by progressive changes of
intrinsic brain network activity.18–21 Here, cognitive networks such as
the default mode network (DMN) are primarily affected.19,22–24 The
DMN is constituted by a distinct connectivity pattern of synchronous
cortical neuronal activity in spatially distant brain regions that include
themedial prefrontal cortex (MPFC), lateral parietal cortices, posterior
cingulate, and hippocampus, which are activated at rest.25–27 There
is a consistent link between APOE4 carrier status and increased A𝛽
burden.8,9,28 Interestingly, the effect of APOE4 on cognitive brain net-
works is present prior to accumulation of A𝛽 , whichmay reflect risk for
AD prior tomanifestation of characteristic AD pathology.29
Another pathological feature of AD is an increased burden of cere-
bral iron deposition.30,31 Although iron continuously accumulates in
the human brain during aging,32–35 recently published postmortem
data suggest an association between the amount of brain iron deposi-
tion and the progression and severity of cognitive decline in AD.36–38
Moreover, associations between APOE4 carrier status, clinical phe-
notypes of increased risk for AD, and increased iron burden in the
CNS have been demonstrated.36,39,40 Paramagnetic susceptibility, as
measured by quantitative susceptibility mapping (QSM) magnetic res-
onance imaging (MRI), has been demonstrated to closely relate to non-
heme iron content of deep brain gray matter.41–44 Although myelin
content is a major determinant of MR phase differences between
cortical gray and white matter,45 recently published histological data
suggest that iron in cortical gray matter regions is a major contrib-
utor to susceptibility measured by QSM.46 This approach is consid-
ered to provide an indirect estimate of non-heme iron in the brain,
and associated risk for oxidative damage.38,47 By applying suitable
post-processing techniques that balance susceptibility measures with
reference regions and correct for heme iron and other non-tissue
iron sources, strong linear correlations resulted between postmortem
gray matter tissue iron concentration and QSM measurements.43,48
Consistently, several QSM-MRI studies demonstrated an associa-
tion between increased tissue magnetic susceptibility, AD, and AD-
risk phenotypes.33,40,49,50 Considering possible damaging impacts of
brain iron burden on brain tissue by increased oxidative stress and
redox activity,51–56 as well as programmed cell death conferred by
ferroptosis,57,58 APOEmight be amoderator for iron-related oxidative
brain damage in individuals at risk for AD.36,59 In this context, corti-
cal iron burden might indicate early cortical neurodegenerative alter-
ations, as suggested by earlier published data of ours on brain iron in
mild cognitive impairment.40
Considering these prior studies, and allowing for the published
evidence on earliest APOE4-moderated DMN alterations in cog-
nitively unimpaired adults,29,60 we hypothesized that APOE4 may
moderate the effects of increased cortical iron on cortical function-
ality, as reflected by DMN connectivity. Moreover, we hypothesized
that APOE4-related changes should (a) be reflected by altered DMN
activity and (b) precede the manifestation of significant AD pathology
and cognitive dysfunction. To test this hypothesis, a study sample
HIGHLIGHTS
• Three-dimensional (3D) gradient recalled echo magnetic
resonance imaging for quantitative susceptibilitymapping
(QSM) and 18F-flutemetamol positron emission tomogra-
phy for amyloid-𝛽 (A𝛽) in healthy old-aged adults.
• Spatial definition and assessment of the defaultmode net-
work (DMN) by group independent component analysis.
• Synergistic effects of iron (as measured by QSM) and
APOE 𝜀4 allele (APOE4) on DMN connectivity.
• Interactive effects of APOE4 and QSM-iron may precede
A𝛽 pathology.
• APOE4 may accelerate brain iron accumulation associ-
ated DMNdisintegrity.
RESEARCH INCONTEXT
1. The apolipoprotein E 𝜀4 allele (APOE4) is the strongest
known genetic risk factor for sporadic Alzheimer’s
disease (AD). APOE4-associated impairment of brain-
network connectivity manifests prior to dementia. Con-
sidering recent reports on relationships between cerebral
iron load, genetic risk, and progression of AD, our study
aims at investigating the effects of APOE4on cortical iron
and cortical network connectivity in non-demented old-
aged adults. Brain iron may be non-invasively inferred on
by its paramagnetic properties using quantitative suscep-
tibilitymapping (QSM)magnetic resonance imaging.QSM
is considered to provide an indirect estimate of non-heme
iron.
2. Our findings suggest that APOE4 may moderate iron
effects on brain functionality, as reflected by altered syn-
chronized network activity, which is consistent with ear-
lier reports on APOE4-related default mode network
alterations.Additional studies areneeded to clarifymech-
anisms implicated in the interactionbetweenAPOE4, cor-
tical iron burden, and progression of cortical dysfunction
in AD.
of cognitively healthy, old-aged study participants was recruited.
All participants received genotyping for detection of APOE4 carrier
status,2 and 18F-flutemetamol positron emission tomography (PET)
for assessing brain A𝛽 burden.61,62 Blood oxygen level–dependent
(BOLD) functional MRI (fMRI) at rest was performed for assessing
intrinsic network connectivity, and the CONN toolbox63 was used to
identify the DMN by independent component analysis (ICA)64 and
statistical testing for interactive effects of APOE4 and cortical iron
load, inferred from graymatter susceptibility.
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2 MATERIALS AND METHODS
2.1 Study sample
The study sample included 69 cognitively healthy old-aged adults
(32 female, 37 male; mean age [SD] 66.1 [7.25] years, range 51–
80 years, mean education [SD] 15.99 [2.77] years, range 11–20)
recruited in the cantone Zurich, Switzerland, from an ongoing study at
our center.65 Study procedures were in concordance with regulations
issued by the local, cantonal ethics authority (Kantonale Ethikkommis-
sion Zürich, www.kek.zh.ch), good clinical practice, and with the Dec-
laration of Helsinki.66 Written informed consent was obtained from
all participants before inclusion in the study. Inclusion criteria were
age between 50 and 80 years, unimpaired overall cognitive status as
indicated by Mini-Mental State Examination (MMSE) ≥27/30, neu-
ropsychological testing, and comprehensive psychiatric examination.
Exclusion criteria were presence of any condition possibly affecting
cognition, any current medication or substance abuse with prompt
effects on cognition, serious medical or psychiatric illness, and evi-
dence of infarction or inflammation on cranial MRI. Furthermore, sub-
jects with contraindications to MRI or PET, clinically relevant changes
in red blood count, or significant exposure to radiation were excluded.
After inclusion, all participants received standardized cognitive testing
and a clinical workup, including medical history, blood sampling, and
genotyping of APOE as described earlier.65 The study population was
dichotomized based on presence of theAPOE4 genotype (“APOE4 car-
riers” vs “non-carriers”), for stratification by genetic risk for sporadic,
late-onset AD.4
2.2 Cognitive assessment of participants
Screening for cognitive impairment was performed by applying the
MMSE67 and the Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) neuropsychological battery.68Moreover, the delayed
recall Verbal Learning and Memory Test (VLMT)69 was used to assess
episodic memory performance, the Boston Naming Test for confronta-
tional word retrieval,70 the Stroop interference test71 as a measure of
executive function, and Trail Making Test, Section B divided by Section
A (TMTB/A) for assessment of mental flexibility.72
2.3 Acquisition ofMRI data andQSM
Imaging of all 69 participants was conducted using a 3T GE SIGNA
PET-MR whole-body scanner (GE Medical Systems, Milwaukee, WI)
equipped with an 8-channel head coil. For anatomical referencing
and automated image segmentation, T1-weighted BRAVO images
(TI = 450 ms, voxel size = 1 × 1 × 1 mm3, flip-angle = 12◦, ASSET
factor = 2, scan time = 6:00 minutes) were acquired. MR phase mea-
surements used for QSM calculation were collected using a multi-
echo 3D gradient recalled echo (GRE) sequence with six echoes
(TR/TE1/ΔTE= 40/6/4ms, voxel size= 1× 1× 1mm3, flip angle= 15◦,
bandwidth = ±62.5 kHz, flow compensated, ASSET factor = 2, scan
time = 7:53 minutes). For investigating BOLD synchronicity at rest
(open eyes), a T2∗-weighted single-shot gradient echo-planar imag-
ing sequence was used to record 200 functional volumes (repetition
time (TR) = 2.547 s; echo time (TE) = 13.8 ms; matrix = 64 × 64; flip
angle = 90◦, total scan time = 8.49 minutes), with 46 slices per volume
(voxel size= 3.75 × 3.75 × 3.6mm3) for whole-brain coverage.
For QSM reconstruction, phase data acquired with an echo time
in the range of 18 to 26 ms was used. QSM images were calculated
from the MR phase images using algorithms described previously by
our group40,48,65 using an in-house scriptwritten inMATLAB (MATLAB
2016a,Version9.0). Briefly, processing includedLaplacian-basedphase
unwrapping,41 brain masking using GRE magnitude image acquired at
TE = 14 ms with FSL’s brain extraction tool (BET, FMRIB Oxford, UK),
dividing the unwrapped phase images by 2𝜋*TE to obtain frequency
shift images (Hz) for each echo. For eliminating background fields the
vSHARPmethod42,73wasused (maximumspherical kernel size=4mm,
regularization parameter = 0.05). Spatially confined vascular objects
such as veins and microbleeds were excluded from estimation of
regional susceptibility values. To increase signal-to-noise ratios (SNR),
images resulting from the last three echoes were averaged.74 Sparse
linear equation and least-squares (LSQR)-basedminimizationwas used
for inverse dipole calculations of susceptibility maps,75,76 with deep
frontal white matter as reference.65
2.4 Acquisition of flutemetamol-PET data
18F-flutemetamol-PET was used for determination of participants A𝛽
plaque burden,61,62 as described earlier by our group.65 In brief, an
individual dose of 140 MBq of flutemetamol was injected into the
cubital vein. Late-frame (85—105 minute) PET images were recon-
structed with state of the art time-of-flight algorithms allowing for
attenuation correction maps, which were generated using standard
procedures implemented by the manufacturer. This resulted in 3D
volumes of 18F-flutemetamol retention (matrix = 256 × 256 × 89,
voxel size = 1.17 × 1.17 × 2.78 mm3). Individual measures of cortical
A𝛽 plaque load were calculated based on average 18F retention in a
composite cortical volume of interest, which was normalized to cere-
bellar gray matter composite cortical volume of interest standard
uptake value ratio (COM-SUVR).62 Consistent with earlier studies on
AD and healthy controls, extent of amyloid pathology was assessed in
regard to a COM-SUVR threshold of 1.56.62
2.5 Analysis of functionalMRI data
2.5.1 Data preprocessing
BOLD fMRI data were processed for statistical analysis using “CONN
functional connectivity toolbox” (ver.17.d; www.nitrc.org/projects/
conn),63 “statistical parametricmapping” (SPM12,Version6906),MAT-
LAB (Version 9.0,MathWorks Inc., Natick,MA,USA), and the “statistics
and machine learning toolbox” (Version 10.2). After importing NIFTI
functional and anatomical images into the CONN toolbox, individual
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TABLE 1 Overview of sample demographics, neuropsychological test performance as well as cortical A𝛽 and cortical magnetic susceptibility
measures as mean (±SD)
Whole sample APOE4 no-APOE4 t test (P)
N 69 18 51 -
Females/males 32/37 8/10 24/27 -
Age 66.1 (7.25) 66.28 (5.29) 66.04 (7.87) 0.89
Years of education 15.99 (2.77) 16.56 (2.48) 15.78 (2.87) 0.28
MMSE 29.32 (1.12) 29.12 (1.58) 29.4 (0.89) 0.49
BostonNaming Test 14.64 (0.7) 14.65 (1) 14.64 (0.57) 0.97
CERADword fluency 24.05 (5.34) 22.47 (5.36) 24.62 (5.27) 0.62
TMTB/A 2.24 (0.76) 2.33 (0.88) 2.21 (0.72) 0.64
Stroop 28 (7.12) 28.59 (6.87) 27.79 (7.26) 0.17
Episodic memory (VLMT) 9.34 (3.9) 9 (3.22) 9.47 (4.14) 0.69
Cortical Abeta (18F-flutemetamol SUVR) 1.19 (0.19) 1.28 (0.33) 1.16 (0.11) 0.15
Abeta positives (n> 1.56) 2 2 0 -
Cortical magnetic susceptibility (QSM) 1.85 (0.81) 1.81 (0.65) 1.87 (0.86) 0.78
T test was performed to investigate differences on a group-level between APOE4 carriers (APOE4) and non-carriers (no-APOE4).
Abbreviations: APOE4: Apolipoprotein E ɛ4 allele, MMSE: Mini-Mental State Exam, CERAD: Consortium to Establish a Registry for Alzheimer’s Disease,
TMT A/B: Trail Making Test, Section A divided by Section B, VLMT: Verbal Learning andMemory Test, SUVR: standard uptake value ratio, QSM: quantitative
susceptibility mapping.
fMRI volumes were spatially realigned, and anatomical scans were
coregistered to the mean functional image, corrected for timing dif-
ferences between slices, spatially normalized to montreal neurologi-
cal institute (MNI) template space, and smoothed using an 8 mm full
width at half-maximum Gaussian kernel. The Artifact Detection Tool-
box (ART, https://web.mit.edu/swg/software.htm) was used for detec-
tion and analysis of sources of artifacts in the investigated timeseries
of 200 functional MR-volumes.63
2.5.2 Identification of resting-state networks
To obtain functional connectivity networks of all 69 participants, we
performed group spatial ICA77 as implemented in the CONN toolbox
for data-driven blind source separation of fMRI data and identification
of functional networks, represented by spatially distant patterns of
BOLD synchronicity.64,78–80 The DMN, as a representation of intrinsic
network activity, was identified based on characteristic spatial pat-
terns that included signature regions of MPFC, posterior cingulate
cortex (PCC), and left and right lateral parietal lobes (LPLs).26
2.6 Statistical analysis
The statistical analysis of fMRI data, as well as investigation of APOE4
and paramagnetic tissue iron effects on DMN connectivity, was per-
formed using algorithms implemented in the CONN-toolbox (V17d).63
As such, DMN activity was operationalized by level of BOLD syn-
chronicity (𝛽 weights of connectivity) within the spatial confinement of
the correspondent independent component.77 Reliability of the ICA for
detection of the DMNwas estimated by probability of each voxel iden-
tified by ICA to belong into the DMN by one sample t test. Moreover,
CONNwas used for investigating group differences in DMNactivity as
a function of APOE4 carrier status and cortical magnetic susceptibility
by linear regression and one-way analysis of covariate interaction tests
in order to study the effects of high corticalmagnetic susceptibility and
APOE4 carrier status on DMN activity. False discovery rate was used
to adjust raw P-values for multiple testing (P-FDR).81
Descriptives of the sample data are presented using mean ±SD.
Tests for differences in demographic, clinical, neuropsychological,
or imaging-based (SUVR, QSM) parameters between subjects in the
ApoE4- and no-ApoE4 group were performed with independent sam-
ples t tests. A median split of the study sample was used for separation
of participants based on average cortical magnetic susceptibility:
QSM levels above or equal to the group median were categorized
as “high cortical magnetic susceptibility” and QSM levels below the
group median as “low cortical magnetic susceptibility.” The resulting
dichotomous variable was used as a categorical operator of cortical
iron burden.
3 RESULTS
3.1 Characteristics of the study population
Within the study population of 69 participants, 18 carriers of the
APOE4 allele could be identified (allelic frequencies were: APOE
ɛ2/ɛ4 = 1, APOE ɛ3/ɛ4 = 16, APOE ɛ4/ɛ4 = 1). When compar-
ing APOE4 carriers with non-carriers, there were no significant dif-
ferences in demographic characteristics between groups. Moreover,
neuropsychological screening by MMSE as well as domain-specific
testing using the CERAD neuropsychological battery consistently indi-
cated high levels of cognitive performance in all study participants,
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F IGURE 1 Identification of resting-state networks by independent component analysis (ICA) of blood oxygen level–dependent (BOLD) time
course synchronicity at rest. Using ICA, 20 independent components could be identified, representing distinct BOLD time course synchronicity
patterns at rest. Heat maps represent factor loading by voxel for each spatial component, estimated by group ICA (color bar: lowest, blue=−3;
maximum, red=+7, horizontal lines in the green area= 0)
F IGURE 2 Spatial definition of the default mode network (DMN) based on blood oxygen level–dependent (BOLD) time course synchronicity
within independent component 3. Indicated are axial slices indicating brain regions included by component 3. Significance levels of voxel-level
BOLD synchronicity are color coded (T-map, highest values are yellow)
without significant differences between APOE4 carriers and non-
carriers (Table 1). Only in two APOE4 carriers was increased brain
A𝛽 load observable. For the rest of the study population, no sub-
stantial brain amyloid pathology was present, as indicated by average
COM-SUVR (mean (±SD)) of 1.19(0.19) without significant differences
on a group level (APOE4 carriers: 1.28(0.33), non-carriers: 1.16(0.1))
(Table 1). Overall cortical magnetic susceptibility was 1.85 (0.81) ppb,
without significant differences between APOE4 carriers (1.81(0.65)
ppb) and non-carriers (1.87(0.65) ppb) (Table 1).
3.2 Identification and spatial definition of the DMN
By performing group ICA for blind source decomposition of 3D
resting-state BOLD data, 20 spatial components of resting-state
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F IGURE 3 Effect of APOE4 carrier status on default mode network (DMN) activity. DMN activity, as indicated by synchronicity of blood
oxygen level–dependent (BOLD) time courses, is associated with APOE4 carrier status (F-map, highest values are yellow)
F IGURE 4 Effect of cortical iron burden on default mode network (DMN) activity. DMN activity is increased in study participants with high
cortical iron (estimated byQSM) (F-map, highest values are yellow)
network activity could be identified based on factor loading by voxel
(Figure 1). These represented established functional brain networks,
including one consistent with the DMN (component #3: T(68) = 4.07,
P(FDR)= 0.0024, k_min= 24), as defined by a spatial pattern ofMPFC,
hippocampus, parahippocampal formation, PCC, precuneus, and lateral
parietal cortex (Figure 2).
3.3 Synergistic interaction of APOE4 and cortical
iron on default mode network activity
By analysis of covariance, a significant effect of APOE4 carrier status
on increased DMN activity could be observed: F(2,66) = 17.95,
P(FDR) < 0.001. The strongest effects were observed in the
posterior cingulate cortex, precuneus, and lateral parietal cortex
(Figure 3).
Moreover,ANCOVAalso indicated significant effects of cortical iron
burden on connectivity within the DMN component (F(2,66) = 14.24,
P(FDR) < 0.001) (Figure 4). Finally, to compare regression effects
attributable to APOE4 and cortical iron, respectively, a one-way
ANCOVA interaction was performed by using second-level analysis
algorithms included inCONN.63 Additive synergismofAPOE4and iron
effects was indicated by a positive relationship between cortical iron
and DMN connectivity that was associated with APOE4 carrier status
(T(65)= 3.22, P(FDR)< 0.001, Figure 5A). Here, significant iron effects
within the subgroupofAPOE4carrierswereobserved (F(2,16)=10.97,
P(FDR) = 0.0026, Figure 5B). The strongest local effects consistently
resulted for voxels localized in the posterior cingulate cortex, the pre-
cuneus, and lateral parietal cortex (Figures 5A, B).
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F IGURE 5 (A) Synergistic interactions between APOE4 carrier status and cortical iron on default mode network (DMN) activity. Colors
indicate local effect sizes, as generated by second level, one-way analysis of covariance (ANCOVA) interaction analysis (T-map, highest values are
yellow). (B) DMN activity in APOE4 carriers relates to cortical iron burden. DMN activity is increased in APOE4 carriers with high cortical iron, as
indicated by regression (F-map, highest values are yellow)
4 DISCUSSION
We identified a synergistic interaction of cortical gray matter suscep-
tibility (QSM) and BOLD synchronicity at rest, suggesting a modera-
tor effect of APOE4 on the relationship between cortical non-heme
iron and DMN activity. This effect was observable in a population of
old-aged, cognitively healthy adults. Because for the majority of the
investigated participants no significant increase of A𝛽 burden could be
observed, our findings might reflect preclinical brain alterations asso-
ciated with APOE4-related increased risk for AD.
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The current study used established neuropsychological testing for
assessment of cognitive domains typically affected in AD.82Moreover,
all study participants were genotyped for presence of the APOE4
allele, allowing for additional stratification of the study population
by individual risk for AD.1,4 Each participant also was investigated
by 18F-flutemetamol PET to assess brain A𝛽 burden. Flutemetamol
has been used previously for assessing patients with AD,61,62 as well
as cognitively unimpaired old-aged adults.83,84 Although there was
no significant difference between APOE4 carriers and non-carriers
regarding A𝛽 pathology, longitudinal follow-up of our sample might
reveal possible faster accumulation of brain A𝛽 in the APOE4 group,
as suggested by earlier reports.10,85 Considering the synchronicity
of BOLD contrast variation in spatially distinct brain regions a proxy
of neuronal functionality,25,26,86 ICA was performed for detection
and statistical group-inferences.63,77 Blind source decomposition is
capable of identifying many different brain networks from fMRI data
recorded at rest.26,64 In the current study we focused on the DMN,
considering earlier studies that provide evidence that DMNconnectiv-
ity is an indicator of cognitive functionality,25,27,87 which is affected at
early, preclinical stages of AD.18,19,21,22,84 Although the chosen focus
on theDMNmay be a limitation regarding general inferences on global
intrinsic network activity, the unambiguous spatial characteristics of
the DMN componentmay have facilitated differentiation from compo-
nents representing noise. Iron burden was assessed using QSM,44,47,88
which is a potential pathology in AD and AD-risk populations.40,49,50,89
Aclose association between paramagnetic susceptibility in graymatter
brain regions (with low myelin content) and high tissue iron content
is supported by post mortem analysis of deep brain gray matter.43,90
Recently published histological data on cortical and deep gray matter
regions furthermore support a positive relationship betweenQSMand
iron, and an inverse relationship betweenQSMandmyelin.46 Although
paramagnetic susceptibility in human graymatter is regarded as a valid
measure of non-heme iron,38,91 particularly cortical susceptibility
measures should be interpreted carefully. When inferring on local
non-heme iron, myelin may have a confounding impact due to its phase
shifting capacity.45 Moreover, there may be a relationship between
susceptibility measured by locally increased BOLD contrast and QSM.
Although the current study investigated BOLD synchronicity over
time rather than local increases of BOLD contrast, the fact that BOLD
and QSMmay not be completely independent might nevertheless rep-
resent another limitation of our experimental approach. In addition,
QSM at higher spatial resolution might reduce the risk of confounding
heme iron by vascular objects that may have been missed due to SNR
limitations of the 3 Tesla GRE sequence applied here. Further studies
implying an additional, independent measure of blood flow might
provide insight on the interdependence of bothmeasures.
Although our data are consistent with earlier reports on an associa-
tion between APOE4 and altered DMNproperties in preclinical stages
of AD,29 our findings of an association between APOE4 and increased
DMN connectivity may be consistent with earlier considerations that
increased DMN connectivity might represent characteristic phenom-
ena in populations at risk for AD.84Moreover, the finding of a genotype
effect may corroborate biological relevance of our observation. Our
main finding was that APOE4 effects synergistically interacted with
effects associated with increased brain iron (as estimated by QSM). To
our knowledge no interactive effects between magnetic susceptibility,
as a reflection of iron, andAPOE4onDMNactivity have been reported
so far. However, our findings support earlier considerations that detri-
mental effects associated with increased brain iron may be promoted
by the APOE4 genotype.36,59,89
Although the APOE4 genotype alone is not associated with
increased iron,37 increased prevalence of APOE4 in cognitively
impaired individualswith higher levels of brain ironmight reflect accel-
erated cognitive deterioration.39,40Moreover, recently published data
suggest that alterations of cortical networks such as theDMNmay also
indicate progression of tau pathology.92,93 Here, additional longitudi-
nal studies are needed to carefully investigate potential interactions
between pathological tau and iron in neurodegenerative disease and
healthy aging.94Our current findings of a possibly synergistic impact of
paramagnetic susceptibility and APOE4 on BOLD synchronicity within
the DMNmight support recently suggested therapeutic interventions
aimed at brain iron load54,95 but also restoring physiological network
architecture within the neocortex.96 Recent studies suggest poten-
tially deleterious effects of unbound iron by oxidative stress52,97 or
programmed cell death such as ferroptosis,58 an association of brain
iron burden with life style,98 and a possible role of iron for maintained
cognitive function at old age.65 Thus, longitudinal cohort studies are
needed to better understand the interplay between altered MR mea-
sures of cortical susceptibility, its relationship to dysbalanced brain
iron homeostasis, and APOE4-related risk for AD.
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